135 related articles for article (PubMed ID: 33537135)
1.
Mohanty S; Mahapatra A
Ann Med Surg (Lond); 2021 Feb; 62():228-230. PubMed ID: 33537135
[TBL] [Abstract][Full Text] [Related]
2. Study on MICs of Tigecycline in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae (CRE) at a Tertiary Care Centre in North India.
Khare V; Gupta P; Haider F; Begum R
J Clin Diagn Res; 2017 Mar; 11(3):DC18-DC21. PubMed ID: 28511383
[TBL] [Abstract][Full Text] [Related]
3. Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial.
Giammanco A; Calà C; Fasciana T; Dowzicky MJ
mSphere; 2017; 2(1):. PubMed ID: 28124025
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012.
Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P
J Glob Antimicrob Resist; 2014 Sep; 2(3):179-182. PubMed ID: 27873726
[TBL] [Abstract][Full Text] [Related]
6. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
[TBL] [Abstract][Full Text] [Related]
7. Tigecycline Susceptibility of Klebsiella pneumoniae Complex and Escherichia coli Isolates from Companion Animals: The Prevalence of Tigecycline-Nonsusceptible K. pneumoniae Complex, Including Internationally Expanding Human Pathogenic Lineages.
Sato T; Harada K; Usui M; Tsuyuki Y; Shiraishi T; Tamura Y; Yokota SI
Microb Drug Resist; 2018; 24(6):860-867. PubMed ID: 29232167
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P; Mokaddas E
Diagn Microbiol Infect Dis; 2014 May; 79(1):54-9. PubMed ID: 24582580
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.
Kelesidis T; Karageorgopoulos DE; Kelesidis I; Falagas ME
J Antimicrob Chemother; 2008 Nov; 62(5):895-904. PubMed ID: 18676620
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.).
Stefani S; Dowzicky MJ
Pharmaceuticals (Basel); 2016 Nov; 9(4):. PubMed ID: 27898030
[TBL] [Abstract][Full Text] [Related]
11. Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance.
Pournaras S; Koumaki V; Spanakis N; Gennimata V; Tsakris A
Int J Antimicrob Agents; 2016 Jul; 48(1):11-18. PubMed ID: 27256586
[TBL] [Abstract][Full Text] [Related]
12. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.
Zhang Y; Zhao C; Wang Q; Wang X; Chen H; Li H; Zhang F; Wang H
J Antimicrob Chemother; 2020 Sep; 75(9):2609-2615. PubMed ID: 32591806
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017).
Rossolini GM; Stone GG
Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602
[TBL] [Abstract][Full Text] [Related]
17. In vitro susceptibility of tigecycline against multidrug-resistant gram-negative strains: Etest versus agar dilution.
Özkök S; Togan T; Yesilkaya A; Timurkaynak F; Azap ÖK; Arslan H
Chemotherapy; 2014; 60(3):151-6. PubMed ID: 25791941
[TBL] [Abstract][Full Text] [Related]
18. Emergence of a Plasmid-Encoded Resistance-Nodulation-Division Efflux Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in Klebsiella pneumoniae.
Lv L; Wan M; Wang C; Gao X; Yang Q; Partridge SR; Wang Y; Zong Z; Doi Y; Shen J; Jia P; Song Q; Zhang Q; Yang J; Huang X; Wang M; Liu JH
mBio; 2020 Mar; 11(2):. PubMed ID: 32127452
[TBL] [Abstract][Full Text] [Related]
19. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009).
Sader HS; Farrell DJ; Jones RN
Diagn Microbiol Infect Dis; 2011 Feb; 69(2):223-7. PubMed ID: 21251571
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
Nicasio AM; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2009 Jul; 53(7):2756-61. PubMed ID: 19364850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
